Hikma Pharmaceuticals PLC (“Hikma”) , the fast growing multinational pharmaceutical group, announces that its Abbreviated New Drug Application (“ANDA”) for Neostigmine Methylsulfate Injection USP, 5 mg/10 mL and 10 mg/10 mL, multiple-dose vials has been approved by the U.S. Food and Drug Administration (“FDA”) and that it has launched this product in the US market.
[adsense:336x280:8701650588]
Neostigmine Methylsulfate injection, a cholinesterase inhibitor, is indicated for reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBA) after surgery. According to IMS Health, sales of Neostigmine Methylsulfate Injection in the US market were approximately $264 million for the 12 months ending November 2015.
[adsense:468x15:2204050025]
Said Darwazah, Chairman and CEO of Hikma, said, “This approval demonstrates our strong regulatory capabilities and the successful execution of our strategy to develop a more differentiated injectable product portfolio."
